144 related articles for article (PubMed ID: 37983014)
1. A retrospective study of Pipelle endometrial biopsy for ovarian, fallopian tube, and peritoneal cancers.
Tamura R; Kitani Y; Takahashi K; Yamaguchi M; Nishikawa N; Kawasaki T; Kikuchi A
J Obstet Gynaecol; 2023 Dec; 43(2):2283162. PubMed ID: 37983014
[TBL] [Abstract][Full Text] [Related]
2. Early detection of ovarian and fallopian tube cancer by examination of cytological samples from the endometrial cavity.
Otsuka I; Kameda S; Hoshi K
Br J Cancer; 2013 Aug; 109(3):603-9. PubMed ID: 23868002
[TBL] [Abstract][Full Text] [Related]
3. Utility of peritoneal washing cytology in staging and prognosis of ovarian and fallopian tube neoplasms: a 10-year retrospective analysis.
Davidson W; Madan R; O'Neil M; Tawfik OW; Fan F
Ann Diagn Pathol; 2016 Jun; 22():54-7. PubMed ID: 27180061
[TBL] [Abstract][Full Text] [Related]
4. Are all pelvic (nonuterine) serous carcinomas of tubal origin?
Przybycin CG; Kurman RJ; Ronnett BM; Shih IeM; Vang R
Am J Surg Pathol; 2010 Oct; 34(10):1407-16. PubMed ID: 20861711
[TBL] [Abstract][Full Text] [Related]
5. A detailed morphological and immunohistochemical comparison of primary endometrial and tubo-ovarian high-grade serous carcinomas and their corresponding omental metastases.
Ruba S; Doherty D; Stewart CJR
Pathology; 2020 Feb; 52(2):197-205. PubMed ID: 31870502
[TBL] [Abstract][Full Text] [Related]
6. Recurrence patterns of advanced ovarian, fallopian tube, and peritoneal cancers after complete cytoreduction during interval debulking surgery.
Usami T; Kato K; Taniguchi T; Abe A; Nomura H; Yamamoto A; Matoda M; Okamoto S; Kondo E; Omatsu K; Kawamata Y; Takeshima N
Int J Gynecol Cancer; 2014 Jul; 24(6):991-6. PubMed ID: 24905612
[TBL] [Abstract][Full Text] [Related]
7. Management of epithelial cancer of the ovary, fallopian tube, and primary peritoneum. Short text of the French Clinical Practice Guidelines issued by FRANCOGYN, CNGOF, SFOG, and GINECO-ARCAGY, and endorsed by INCa.
Lavoue V; Huchon C; Akladios C; Alfonsi P; Bakrin N; Ballester M; Bendifallah S; Bolze PA; Bonnet F; Bourgin C; Chabbert-Buffet N; Collinet P; Courbiere B; De la Motte Rouge T; Devouassoux-Shisheboran M; Falandry C; Ferron G; Fournier L; Gladieff L; Golfier F; Gouy S; Guyon F; Lambaudie E; Leary A; Lecuru F; Lefrere-Belda MA; Leblanc E; Lemoine A; Narducci F; Ouldamer L; Pautier P; Planchamp F; Pouget N; Ray-Coquard I; Rousset-Jablonski C; Senechal-Davin C; Touboul C; Thomassin-Naggara I; Uzan C; You B; Daraï E
Eur J Obstet Gynecol Reprod Biol; 2019 May; 236():214-223. PubMed ID: 30905627
[TBL] [Abstract][Full Text] [Related]
8. Wilms tumor gene immunoreactivity in primary serous carcinomas of the fallopian tube, ovary, endometrium, and peritoneum.
Hashi A; Yuminamochi T; Murata S; Iwamoto H; Honda T; Hoshi K
Int J Gynecol Pathol; 2003 Oct; 22(4):374-7. PubMed ID: 14501819
[TBL] [Abstract][Full Text] [Related]
9. Inherited mutations in fallopian tube, ovarian and primary peritoneal carcinoma: Changes in diagnoses and mutational frequency over 20 years.
Weiss AS; Swisher E; Pennington KP; Radke M; Khasnavis N; Garcia RL; Kilgore MR; Lee MK; Norquist BM
Gynecol Oncol; 2020 Oct; 159(1):214-220. PubMed ID: 32709535
[TBL] [Abstract][Full Text] [Related]
10. Comparison of treatment outcomes between first-line chemotherapy with or without bevacizumab for advanced ovarian, fallopian tube, and primary peritoneal cancer (Tohoku gynecologic cancer unit: TGCU-RS001 study).
Shoji T; Takatori E; Nagasawa T; Kagabu M; Baba T; Shigeto T; Matsumura Y; Shimizu D; Terada Y; Seino M; Ohta T; Nagase S; Shigeta S; Tokunaga H; Shimada M; Kaiho-Sakuma M; Furukawa S; Soeda S; Watanabe T; Takahashi F; Yokoyama Y
Int J Clin Oncol; 2022 Dec; 27(12):1874-1880. PubMed ID: 36214925
[TBL] [Abstract][Full Text] [Related]
11. Management of epithelial cancer of the ovary, fallopian tube, and primary peritoneum. Long text of the Joint French Clinical Practice Guidelines issued by FRANCOGYN, CNGOF, SFOG, and GINECO-ARCAGY, and endorsed by INCa. Part 1: Diagnostic exploration and staging, surgery, perioperative care, and pathology.
Lavoue V; Huchon C; Akladios C; Alfonsi P; Bakrin N; Ballester M; Bendifallah S; Bolze PA; Bonnet F; Bourgin C; Chabbert-Buffet N; Collinet P; Courbiere B; De la Motte Rouge T; Devouassoux-Shisheboran M; Falandry C; Ferron G; Fournier L; Gladieff L; Golfier F; Gouy S; Guyon F; Lambaudie E; Leary A; Lecuru F; Lefrere-Belda MA; Leblanc E; Lemoine A; Narducci F; Ouldamer L; Pautier P; Planchamp F; Pouget N; Ray-Coquard I; Rousset-Jablonski C; Senechal-Davin C; Touboul C; Thomassin-Naggara I; Uzan C; You B; Daraï E
J Gynecol Obstet Hum Reprod; 2019 Jun; 48(6):369-378. PubMed ID: 30936027
[TBL] [Abstract][Full Text] [Related]
12. Fallopian tube origin of supposed ovarian high-grade serous carcinomas.
Diniz PM; Carvalho JP; Baracat EC; Carvalho FM
Clinics (Sao Paulo); 2011; 66(1):73-6. PubMed ID: 21437439
[TBL] [Abstract][Full Text] [Related]
13. Mucosal Proliferations in Completely Examined Fallopian Tubes Accompanying Ovarian Low-grade Serous Tumors: Neoplastic Precursor Lesions or Normal Variants of Benign Mucosa?
Wolsky RJ; Price MA; Zaloudek CJ; Rabban JT
Int J Gynecol Pathol; 2018 May; 37(3):262-274. PubMed ID: 28700429
[TBL] [Abstract][Full Text] [Related]
14. Do deeper sections increase the frequency of detection of serous tubal intraepithelial carcinoma (STIC) in the "sectioning and extensively examining the FIMbriated end" (SEE-FIM) protocol?
Mahe E; Tang S; Deb P; Sur M; Lytwyn A; Daya D
Int J Gynecol Pathol; 2013 Jul; 32(4):353-7. PubMed ID: 23722507
[TBL] [Abstract][Full Text] [Related]
15. [Significance and expression of PAX8, PAX2, p53 and RAS in ovary and fallopian tubes to origin of ovarian high grade serous carcinoma].
Mao YN; Zeng LX; Li YH; Liu YZ; Wu JY; Li L; Wang Q
Zhonghua Fu Chan Ke Za Zhi; 2017 Oct; 52(10):687-696. PubMed ID: 29060967
[No Abstract] [Full Text] [Related]
16. Positron emission tomography (PET) and magnetic resonance imaging (MRI) for assessing tumour resectability in advanced epithelial ovarian/fallopian tube/primary peritoneal cancer.
Roze JF; Hoogendam JP; van de Wetering FT; Spijker R; Verleye L; Vlayen J; Veldhuis WB; Scholten RJ; Zweemer RP
Cochrane Database Syst Rev; 2018 Oct; 10(10):CD012567. PubMed ID: 30298516
[TBL] [Abstract][Full Text] [Related]
17. Mucosal carcinoma of the fallopian tube coexists with ovarian cancer of serous subtype only: a study of Japanese cases.
Maeda D; Ota S; Takazawa Y; Ohashi K; Mori M; Imamura T; Nakagawa S; Yano T; Taketani Y; Fukayama M
Virchows Arch; 2010 Nov; 457(5):597-608. PubMed ID: 20872013
[TBL] [Abstract][Full Text] [Related]
18. Cancer of the ovary, fallopian tube, and peritoneum.
Berek JS; Kehoe ST; Kumar L; Friedlander M
Int J Gynaecol Obstet; 2018 Oct; 143 Suppl 2():59-78. PubMed ID: 30306591
[TBL] [Abstract][Full Text] [Related]
19. Increase of fallopian tube and decrease of ovarian carcinoma: fact or fake?
Höhn AK; Klagges S; Gläser A; Taubenheim S; Dornhöfer N; Einenkel J; Hiller GGR; Brambs CE; Horn LC
J Cancer Res Clin Oncol; 2021 Mar; 147(3):911-925. PubMed ID: 32915262
[TBL] [Abstract][Full Text] [Related]
20. Validity of the 2014 FIGO Stage IIIA1 Subclassification for Ovarian, Fallopian Tube, and Peritoneal Cancers.
Matsuoka A; Tate S; Nishikimi K; Iwamoto M; Otsuka S; Shozu M
In Vivo; 2022; 36(5):2453-2460. PubMed ID: 36099140
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
